Butterfly iQ/iQ+ Ultrasound System vs Fibresolve

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Butterfly iQ/iQ+ Ultrasound System

by Butterfly Network

Fibresolve

by Imvaria

AI Verdict

These two tools are adjacent rather than direct competitors. Butterfly iQ/iQ+ is a portable ultrasound system for real-time, whole-body imaging across various specialties, leveraging AI for image acquisition and basic measurements. In contrast, Fibresolve is a cloud-based AI diagnostic service that analyzes existing CT scans specifically for interstitial lung disease and idiopathic pulmonary fibrosis, providing diagnostic support rather than imaging acquisition.

Choose Butterfly iQ/iQ+ Ultrasound System if…

Choose the Butterfly iQ/iQ+ Ultrasound System if you need a versatile, portable, whole-body ultrasound solution for point-of-care diagnostics and procedural guidance across various specialties like critical care, emergency medicine, and sports medicine. Its single-probe, 'Ultrasound-on-Chip' technology and mobile device compatibility make it ideal for immediate imaging in diverse settings, from hospital departments to rural communities.

View Butterfly iQ/iQ+ Ultrasound System →

Choose Fibresolve if…

Choose Fibresolve if you require an AI-powered diagnostic aid for suspected interstitial lung disease (ILD), particularly for differentiating idiopathic pulmonary fibrosis (IPF) from other ILDs using non-invasive analysis of standard chest CT scans. This cloud-based service is best suited for pulmonologists and radiologists seeking to supplement clinical diagnosis and potentially avoid invasive testing in challenging cases.

View Fibresolve →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Butterfly iQ/iQ+ Ultrasound System	Fibresolve
Pricing	Device purchase + mandatory annual subscription.	Not explicitly stated; described as a cost-effective option. the company works with health insurance to manage cost and coverage, noting it is not always covered.
Deployment	Mobile device (iOS/Android) connected to a handheld probe, with cloud-based software.	Cloud-based system
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Unknown

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Butterfly iQ/iQ+ Ultrasound System	Fibresolve
Name	Butterfly iQ/iQ+ Ultrasound System	Fibresolve
Company	Butterfly Network	Imvaria
Description	The Butterfly iQ/iQ+ is a handheld, single-probe, whole-body ultrasound system leveraging Ultrasound-on-Chipu2122 technology and AI-powered tools for accessible, high-quality diagnostic imaging on mobile devices.	Fibresolve is the first FDA-authorized AI diagnostic service in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD), using non-invasive analysis to help drive diagnosis.
Key Features	Ultrasound-on-Chipu2122 Technology (single silicon chip replaces multiple probes); Whole-body imaging with a single handheld probe; Compatible with iOS and Android mobile devices; 20+ anatomical presets and six imaging modes (B-Mode, M-Mode, Color Doppler, Power Doppler, Pulsed Wave Doppler); AI-powered imaging tools (Auto Bladder Volume Capture, Auto B-Line Counter, NeedleVizu2122); Unlimited HIPAA and GDPR-compliant cloud storage (Butterfly Cloud); Military-grade durability (4-foot drop resistance, IP67 water/dust resistant); Teleguidance functionality for remote assistance	AI-based software for diagnosis of lung fibrosis; Non-invasive analysis using standard chest CT scans; Serves as an adjunct to clinical diagnosis; Aids in differentiating IPF from other ILDs; Generates streamlined Fibresolve reports; Integration-free workflow for clinical practices; Assigned CPT billing codes by the American Medical Association (AMA); Trained on thousands of cases with tissue pathology and lung fibrosis follow-up